Neumora Therapeutics (NMRA) Operating Leases (2022 - 2026)

Neumora Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $119000.0 for Q1 2026.

• On a quarterly basis, Operating Leases changed N/A year-over-year to $119000.0 in Q1 2026; TTM through Mar 2026 was $119000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $193000.0, changed N/A from the prior year.
• Operating Leases fell to $119000.0 in Q1 2026 per NMRA's latest filing, from $193000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $5.1 million in Q4 2022 and bottomed at $119000.0 in Q1 2026.
• The 5-year median for Operating Leases is $638500.0 (2024), against an average of $1.4 million.
• Biggest YoY gain for Operating Leases was 63.47% in 2023; the steepest drop was 63.47% in 2023.
• Year by year, Operating Leases stood at $5.1 million in 2022, then sank by 63.47% to $1.9 million in 2023, then slumped by 49.38% to $938000.0 in 2024, then sank by 79.42% to $193000.0 in 2025, then plunged by 38.34% to $119000.0 in 2026.
• Per Business Quant, the three latest NMRA Operating Leases figures stand at $119000.0 (Q1 2026), $193000.0 (Q4 2025), and $267000.0 (Q3 2025).